The Ability to Generate Senescent Progeny As a Mechanism Underlying Breast Cancer Cell Heterogeneity

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2010 Jun 30

PMID 20585577

Citations 14

Authors

Mine Mumcuoglu

Sevgi Bagislar

Haluk Yuzugullu

Hani Alotaibi

Serif Senturk

Pelin Telkoparan

Bala Gur-Dedeoglu

Burcu Cingoz

Betul Bozkurt

Uygar H Tazebay

Isik G Yulug

K Can Akcali

Mehmet Ozturk

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is a remarkably heterogeneous disease. Luminal, basal-like, "normal-like", and ERBB2+ subgroups were identified and were shown to have different prognoses. The mechanisms underlying this heterogeneity are poorly understood. In our study, we explored the role of cellular differentiation and senescence as a potential cause of heterogeneity.

Methodology/principal Findings: A panel of breast cancer cell lines, isogenic clones, and breast tumors were used. Based on their ability to generate senescent progeny under low-density clonogenic conditions, we classified breast cancer cell lines as senescent cell progenitor (SCP) and immortal cell progenitor (ICP) subtypes. All SCP cell lines expressed estrogen receptor (ER). Loss of ER expression combined with the accumulation of p21(Cip1) correlated with senescence in these cell lines. p21(Cip1) knockdown, estrogen-mediated ER activation or ectopic ER overexpression protected cells against senescence. In contrast, tamoxifen triggered a robust senescence response. As ER expression has been linked to luminal differentiation, we compared the differentiation status of SCP and ICP cell lines using stem/progenitor, luminal, and myoepithelial markers. The SCP cells produced CD24+ or ER+ luminal-like and ASMA+ myoepithelial-like progeny, in addition to CD44+ stem/progenitor-like cells. In contrast, ICP cell lines acted as differentiation-defective stem/progenitor cells. Some ICP cell lines generated only CD44+/CD24-/ER-/ASMA- progenitor/stem-like cells, and others also produced CD24+/ER- luminal-like, but not ASMA+ myoepithelial-like cells. Furthermore, gene expression profiles clustered SCP cell lines with luminal A and "normal-like" tumors, and ICP cell lines with luminal B and basal-like tumors. The ICP cells displayed higher tumorigenicity in immunodeficient mice.

Conclusions/significance: Luminal A and "normal-like" breast cancer cell lines were able to generate luminal-like and myoepithelial-like progeny undergoing senescence arrest. In contrast, luminal B/basal-like cell lines acted as stem/progenitor cells with defective differentiation capacities. Our findings suggest that the malignancy of breast tumors is directly correlated with stem/progenitor phenotypes and poor differentiation potential.

Citing Articles

New Mitochondria-Targeted Fisetin Derivative Compromises Mitophagy and Limits Survival of Drug-Induced Senescent Breast Cancer Cells.

Rzeszutek I, Cybularczyk-Cecotka M, Deregowska A, Stec P, Wnuk M, Kolodziej O J Med Chem. 2024; 67(19):17676-17689.

PMID: 39322603 PMC: 11472315. DOI: 10.1021/acs.jmedchem.4c01664.

Fibroblast heterogeneity and functions: insights from single-cell sequencing in wound healing, breast cancer, ovarian cancer and melanoma.

Lujano Olazaba O, Farrow J, Monkkonen T Front Genet. 2024; 15:1304853.

PMID: 38525245 PMC: 10957653. DOI: 10.3389/fgene.2024.1304853.

TRIM27 Functions as a Novel Oncogene in Non-Triple-Negative Breast Cancer by Blocking Cellular Senescence through p21 Ubiquitination.

Xing L, Tang X, Wu K, Huang X, Yi Y, Huan J Mol Ther Nucleic Acids. 2020; 22:910-923.

PMID: 33251042 PMC: 7666371. DOI: 10.1016/j.omtn.2020.10.012.

Senescence-Associated Pro-inflammatory Cytokines and Tumor Cell Plasticity.

Vernot J Front Mol Biosci. 2020; 7:63.

PMID: 32478091 PMC: 7237636. DOI: 10.3389/fmolb.2020.00063.

SNHG6 is upregulated in primary breast cancers and promotes cell cycle progression in breast cancer-derived cell lines.

Jafari-Oliayi A, Asadi M Cell Oncol (Dordr). 2019; 42(2):211-221.

PMID: 30826970 DOI: 10.1007/s13402-019-00422-6.

References

Gur-Dedeoglu B, Konu O, Kir S, Ozturk A, Bozkurt B, Ergul G . A resampling-based meta-analysis for detection of differential gene expression in breast cancer. BMC Cancer. 2009; 8:396. PMC: 2631593. DOI: 10.1186/1471-2407-8-396. View

Honeth G, Bendahl P, Ringner M, Saal L, Gruvberger-Saal S, Lovgren K . The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008; 10(3):R53. PMC: 2481503. DOI: 10.1186/bcr2108. View

Kiyono T, Foster S, Koop J, McDougall J, Galloway D, Klingelhutz A . Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature. 1998; 396(6706):84-8. DOI: 10.1038/23962. View

Stingl J, Caldas C . Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer. 2007; 7(10):791-9. DOI: 10.1038/nrc2212. View

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N . Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2005; 25(15):2273-84. DOI: 10.1038/sj.onc.1209254. View

Shipitsin M, Campbell L, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J . Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007; 11(3):259-73. DOI: 10.1016/j.ccr.2007.01.013. View

Stingl J . Detection and analysis of mammary gland stem cells. J Pathol. 2008; 217(2):229-41. DOI: 10.1002/path.2457. View

Dubik D, Shiu R . Mechanism of estrogen activation of c-myc oncogene expression. Oncogene. 1992; 7(8):1587-94. View

10.

Dimri G, Lee X, Basile G, Acosta M, Scott G, Roskelley C . A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995; 92(20):9363-7. PMC: 40985. DOI: 10.1073/pnas.92.20.9363. View

11.

Beausejour C, Krtolica A, Galimi F, Narita M, Lowe S, Yaswen P . Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 2003; 22(16):4212-22. PMC: 175806. DOI: 10.1093/emboj/cdg417. View

12.

Shyamala G, Chou Y, Cardiff R, Vargis E . Effect of c-neu/ ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: implications for breast cancer biology. Cancer Res. 2006; 66(21):10391-8. DOI: 10.1158/0008-5472.CAN-06-0321. View

13.

Booth B, Smith G . Estrogen receptor-alpha and progesterone receptor are expressed in label-retaining mammary epithelial cells that divide asymmetrically and retain their template DNA strands. Breast Cancer Res. 2006; 8(4):R49. PMC: 1779481. DOI: 10.1186/bcr1538. View

14.

Sotiriou C, Neo S, McShane L, Korn E, Long P, Jazaeri A . Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003; 100(18):10393-8. PMC: 193572. DOI: 10.1073/pnas.1732912100. View

15.

Ford C, Ekstrom E, Andersson T . Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells. Proc Natl Acad Sci U S A. 2009; 106(10):3919-24. PMC: 2656180. DOI: 10.1073/pnas.0809516106. View

16.

Wei W, Sedivy J . Differentiation between senescence (M1) and crisis (M2) in human fibroblast cultures. Exp Cell Res. 1999; 253(2):519-22. DOI: 10.1006/excr.1999.4665. View

17.

Berthois Y, Katzenellenbogen J, Katzenellenbogen B . Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A. 1986; 83(8):2496-500. PMC: 323325. DOI: 10.1073/pnas.83.8.2496. View

18.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

19.

Cariou S, Donovan J, Flanagan W, Milic A, Bhattacharya N, Slingerland J . Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A. 2000; 97(16):9042-6. PMC: 16818. DOI: 10.1073/pnas.160016897. View

20.

Wu C, van Riggelen J, Yetil A, Fan A, Bachireddy P, Felsher D . Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A. 2007; 104(32):13028-33. PMC: 1941831. DOI: 10.1073/pnas.0701953104. View